UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
December
16, 2020
AYTU
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-38247
|
47-0883144
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
373
Inverness Parkway, Suite 206
Englewood,
CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-580
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AYTU
|
The
NASDAQ Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 - Other Events
Aytu
BioScience, Inc. (the “Company”) filed Form 8-K on
December 2, 2020, communicating the Company’s recently
established purchasing relationship with a U.S. supplier of
Emergency Use Authorization (EUA) authorized antigen tests. Antigen
tests rapidly detect the presence of the SARS-CoV-2 virus antigen
via a nasopharyngeal swab and are used without laboratory
equipment.
An
initial shipment of EUA antigen tests was received by the Company,
and all initial test kit inventory was depleted. Accordingly, the
Company placed a significantly larger order for additional EUA
antigen kits to address higher than anticipated test demand. This
larger shipment of test kits has now been received by the Company,
and customer backorders are being fulfilled. The Company expects
the test kits to contribute incremental revenue for the
Company.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AYTU
BIOSCIENCE, INC.
|
|
|
|
|
|
|
Date: December 16,
2020
|
By:
|
/s/
Joshua
R. Disbrow
|
|
|
|
Joshua R.
Disbrow
|
|
|
|
Chief Executive
Officer
|
|